Skip to main content
OpenTrials
Completed

NCT Number: NCT01612780

Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study

The purpose of this study is to show clinically meaningful improvement in symptom severity after transnasal balloon dilation of the maxillary sinus outflow tract with or without balloon dilation of the frontal or sphenoid sinuses.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Entellus Medical

Plymouth, Minnesota, 55447, United States

About this study

This is a prospective, non-randomized, single arm, post-approval study conducted under a common protocol designed to evaluate outcomes following trans-nasal balloon dilation of the maxillary sinus outflow tract with or without concurrent balloon dilation of the frontal or sphenoid sinuses and without any concomitant conventional sinus surgery (ie, uncinectomy, complete or partial ethmoidectomy).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be at least age 18 years old or older.
  • Be a candidate for transnasal balloon dilation of the maxillary sinus(es) with or without balloon dilation of the frontal or sphenoid sinus(es) using XprESS consistent with the device's Indication for Use.
  • Have a sinus CT scan within 12 months of the procedure date.
  • Be able and willing to provide consent.
  • Be willing to comply with the protocol requirements.

Exclusion criteria

  • Have any prior maxillary sinus surgery (eg, antrostomy, uncinectomy).
  • Require any concomitant endoscopic sinus surgery (ESS) or nasal surgery (exception: turbinate reduction) at the time of the study procedure.
  • Have any nasal surgery (eg, septoplasty) or nonmaxillary sinus surgery (eg, frontal sinusotomy, sphenoidotomy, full/partial ethmoidectomy) performed within 3 months prior to enrollment.
  • Have presence of features consistent with sinus fungal disease.
  • Be allergic to nickel or barium sulfate.
  • Be currently participating in any other drug or device clinical studies excluding postapproval or marketing registry studies.

Treatment and study plan

XprESS Multi-Sinus Dilation Tool

Device

Sinus balloon dilation

Other names: Sinus balloon dilation

Primary outcomes

  1. Change in SNOT-20 Score

    Time frame: Baseline and 1-year post procedure

    The 20-item Sino-Nasal Outcomes Test (SNOT-20) is a validated patient-reported outcome measure for assessing the presence and severity of symptoms of chronic rhinosinusitis. Symptoms on the SNOT-20 survey are each rated on a scale from 0 (no problem) to 5 (problem as bad as it can be) and the 20 symptom scores are averaged to provide a total score ranging from 0 to 5. The minimal clinically important difference in the SNOT-20 has been determined to be a reduction greater or equal to 0.8 in the total SNOT-20 score.

Secondary outcomes

  1. Revision Sinus Surgery

    Time frame: 1-year post procedure

    The number of participants who require revision sinus surgery to address continuing sinus symptoms.

  2. Number of Participants With Serious Device and/or Procedure-related Adverse Events

    Time frame: Through 1-year post procedure follow-up

    Serious adverse events that are considered to be possibly, probably, or definitely related to the balloon device and/or dilation procedure.

Sponsors and collaborators

Lead sponsor

Entellus Medical, Inc.

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jun 6, 2012
Registry last updated
Oct 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.